Phase 3 Clinical Trials With Primary Completion Dates in April 2022
This is a list of Phase 3 trials with primary completion dates in April 2022 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|ASND||Ascendis Pharma A/S||2022-04-01||Phase 3||NCT04326374||Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency|
|CANF||Can-Fite BioPharma Ltd.||2022-04-01||Phase 3||NCT03168256||CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis|
|DBVT||DBV Technologies S.A.||2022-04-01||Phase 3||NCT03211247||Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age|
|GKOS||Glaukos Corporation||2022-04-01||Phase 3||NCT03519386||Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%|
|GLYC||GlycoMimetics, Inc.||2022-04-01||Phase 3||NCT03616470||Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia|
|KOD||Kodiak Sciences Inc.||2022-04-01||Phase 3||NCT04592419||A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)|
|KRTX||Karuna Therapeutics, Inc.||2022-04-01||Phase 3||NCT04659161||A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)|
|MCRB||Seres Therapeutics, Inc.||2022-04-01||Phase 3||NCT03183141||ECOSPOR IV: Open-Label Study, Including Study SERES-012 Extension, Evaluating SER-109 in Recurrent Clostridioides Difficile Infection|
|NEPH||Nephros, Inc.||2022-04-01||Phase 3||NCT03534284||Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis|
|OBSV||ObsEva SA||2022-04-01||Phase 3||NCT04335591||Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)|
|RIGL||Rigel Pharmaceuticals, Inc.||2022-04-01||Phase 3||NCT04629703||Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects|
|RIGL||Rigel Pharmaceuticals, Inc.||2022-04-01||Phase 3||NCT03764618||A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA|